RET and non-small cell lung carcinoma: This [19, 20, 21] meta-analysis showed that (I2 < 50%, P > 0.1), the mPFS of RET fusion-positive NSCLC patients treated with RET-TKIs were significantly prolonged to 16.09 months (95%CI: 11.66–20.52, P < 0.05) (Fig. 3).